Avatar
Forbes News source @forbes.com · Jersey City, New Jersey 🇯🇪· Feb 13

#Neuropsychiatry #DrugDevelopment #MentalHealth

Link Preview
www.forbes.com
Startup Organotics Fast Tracks Personalized Brain Drug Trials
Psychiatric drug development has a sobering statistic: nearly 96% of neuropsychiatric drugs fail, including many aimed at autism, bipolar disorder, and schizophrenia.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5

#Pharmaceuticals #ClinicalTrials #DrugDevelopment

Link Preview
www.nasdaq.com
Crinetics To Provide Update On PALSONIFY And Topline Results From Phase 2 Trial Of Atumelnant In CAH
(RTTNews) - Crinetics Pharmaceuticals, Inc.
Avatar
Seeking Alpha News source @seekingalpha.com · Jan 4

#Biotech #DrugDevelopment #Investing

Link Preview
seekingalpha.com
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision (NASDAQ:GHRS)
A positive IND outcome could catalyze further upside, but current valuation reflects significant optimism already priced in.